Healthcare Providers and Services
Company Overview of Karolinska University Hospital
Karolinska University Hospital operates as an acute care hospital in Scandinavia. The company manages patient care, research, and education at its medical centers in Huddinge and Solna; outpatient clinics, laboratories, and services at other hospitals and primary care centers in Stockholm County. It also manages an emergent care clinic. The company offers services in the areas of anesthesiology and intensive care, biomedical engineering, cardiology, center for inherited metabolic diseases, clinical chemistry, clinical genetics, clinical immunology, clinical microbiology, clinical pathology and cytology, clinical pharmacology, clinical physiology, department of nutrition, department of urolog...
Solna, 171 76
Founded in 1940
Key Executives for Karolinska University Hospital
Director of Administration
Director of Human Resources
Head of the Department of Endocrinology and Diabetology
Compensation as of Fiscal Year 2016.
Karolinska University Hospital Key Developments
Karolinska University Hospital Presents at BIO-Europe Spring 2016, Apr-05-2016 02:00 PM
Mar 24 16
Karolinska University Hospital Presents at BIO-Europe Spring 2016, Apr-05-2016 02:00 PM. Venue: Kistamässan Convention Center, Stockholm, Sweden. Speakers: Jeffrey Yachnin, Clinical Trials Unit, Department of Oncology.
Immunicum AB (publ) with Karolinska Institute and Karolinska University Hospital Submit an Application for Starting a Clinical Study with INTUVAX in GIST
Sep 17 15
Immunicum AB (publ) announced that it, together with Karolinska Institute and Karolinska University Hospital, has filed an application with the Swedish Medical Products Agency to start a phase I/II study with the company's therapeutic cancer immune primer INTUVAX®. The safety and efficacy of INTUVAX® in combination with sunitinib in patients with incurable Gastrointestinal Stromal Tumor (GIST) will be examined. The first observations of INTUVAX® in humans looks promising and have made research group wanting to look closely at INTUVAX’s effect on critically ill GIST patients. The study is expected to start at the end of the year and will be conducted at the Karolinska University Hospital during about a year. This is the fourth clinical study with INTUVAX®. The company's most advanced clinical trial is an ongoing phase II study in patients with metastatic renal cell cancer (mRCC). Immunicum also has an ongoing phase I/II study in patients with primary liver cancer and a completed phase I/II study in mRCC where the Company continues to follow overall survival. Up to 12 patients with GIST, showing signs of progression with established second-line treatment with sunitinib (Sutent®, Pfizer) will be included in the study. The patients will obtain two or three doses of INTUVAX. The study design gives Immunicum the opportunity to compare the effect of two and three vaccine doses (for the first six respectively the last six patients in the study). Since Immunicum’s completed phase I/II study in patients with metastatic renal cell carcinoma, including patients with so-called sarcomatoid tumor development, showed signs of synergy between INTUVAX and sunitinib, the GIST patients who progress despite ongoing treatment with sunitinib will remain on sunitinib treatment during at least three months. The study's primary objective is to determine safety and the most important secondary objective is to study whether patients showing progression and resistance to existing treatment after INTUVAX treatment show objective tumor response. Immunicum expects the company's existing cash to cover the financing of the GIST study and that the study will not affect the timing of a potential future fundraising.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries